GLP-1 & Incretin Science

The Attribution Problem Running Through Every Indication

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Cardiovascular, renal and hepatic benefits reported for incretin agonists all occur in participants who also lost substantial weight. Whether the benefit follows from weight reduction or from direct tissue effects cannot be resolved within a trial where both happen together.

Key facts

The problem
Weight and organ benefit are collinear
Affects
SELECT, FLOW, ESSENCE alike
One approach
Subgroups by concomitant therapy
FLOW example
With vs without SGLT2 inhibitor
Another approach
Compare against non-incretin weight loss
Status
unresolved

Why this is not a pedantic question

It determines what the drug is. If organ benefits follow from weight reduction, then any intervention producing equivalent weight loss should produce equivalent benefit, and the incretin is one route among several. If there are direct effects, the compound is doing something bariatric surgery or diet cannot replicate, and the class occupies a different position entirely.

Why a single trial cannot settle it

Collinearity. In any trial of these compounds, the participants who received the drug are the participants who lost weight. The two are not independent variables and cannot be disentangled by statistics applied afterwards. This is a structural feature of the design, not a shortcoming of the analysis.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The mechanistic case for direct effects

GLP-1 receptors are not confined to pancreas and brain. They are described in cardiovascular tissue, kidney and elsewhere, and incretin signalling has been linked to inflammatory and haemodynamic changes independent of glycaemia. That makes direct effects biologically plausible rather than speculative. Plausible is not the same as demonstrated.

How trial teams probe it anyway

By looking at subgroups where an alternative explanation is already saturated. The FLOW analysis of participants with and without concomitant SGLT2 inhibitor use is a good example: if the benefit merely duplicated an established renal mechanism, it should shrink where that mechanism is already engaged. Persistence of effect argues for something additional.

What would actually resolve it

A trial comparing an incretin against a different intervention producing matched weight loss, with organ outcomes as endpoints. That is expensive, slow, ethically complicated and largely has not been done, which is why the question remains open despite being the most important one about this class.

How to read claims in the meantime

Treat organ benefit as demonstrated for the compound as administered, and treat the mechanism as unresolved. Those are compatible positions. A claim that a drug protects the kidney independent of weight loss requires evidence the current trials cannot supply.

Frequently asked questions

Why can't a trial separate weight loss from direct effects?

The participants who received the drug are the participants who lost weight. They are collinear, and no post-hoc statistics can disentangle them.

Are direct effects plausible?

Yes. GLP-1 receptors are described in cardiovascular and renal tissue, and effects on inflammation and haemodynamics have been proposed. Plausible is not demonstrated.

What would settle it?

A trial against a different intervention producing matched weight loss, with organ outcomes as endpoints. That has largely not been done.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.